loading page

Prospective Evaluation of Pregnancy Outcomes after Gestational Exposure to Prazosin
  • +1
  • Natalie Zitoun,
  • M Karen Campbell,
  • D Matsui,
  • Facundo Garcia-Bournissen
Natalie Zitoun
Western University Schulich School of Medicine & Dentistry
Author Profile
M Karen Campbell
Western University Schulich School of Medicine & Dentistry
Author Profile
D Matsui
Western University Schulich School of Medicine & Dentistry
Author Profile
Facundo Garcia-Bournissen
Western University Schulich School of Medicine & Dentistry

Corresponding Author:facugb1@gmail.com

Author Profile

Abstract

Introduction: Prazosin is an antihypertensive medication which can be used to help with post-traumatic stress disorder (PTSD) symptoms. Little data is currently available on its safety in pregnancy. Objective: To assess the fetal and pregnancy safety associated with Prazosin exposures in early Pregnancy. Methods: Subjects were 11 patients who took Prazosin during pregnancy and were counselled at the FRAME clinic in London Health Sciences Centre (Ontario, Canada) between January 1, 2000 to December 31, 2021. Data on their other exposures and pregnancy outcomes were collected from medical records and through telephone questionnaires. Results: It was found that 6 /11 (54.5%) subjects did not report any adverse outcomes and were uneventful pregnancies. There were 2 miscarriages. Birthweights were within the normal range for the remaining 9 pregnancies. Adverse events reported were consistent with background population expectation, including: 1 postpartum hemorrhage, 1 case of preeclampsia, 1 preterm birth, 2 NICU admissions, and 2 caesarean sections. Discussion / Conclusion: For these 11 subjects, pregnancy outcomes after exposure to Prazosin were consistent with typical outcomes from unexposed pregnancies. More data are needed to conclude that Prazosin is safe for use in pregnant subjects. However, the lack of adverse effects above baseline is reassuring to future patients who may be unintentionally exposed to Prazosin while pregnant. Therefore, this study contributes valuable data toward monitoring safety of Prazosin in Pregnancy.
06 Jan 2023Submitted to British Journal of Clinical Pharmacology
09 Jan 2023Submission Checks Completed
09 Jan 2023Assigned to Editor
09 Jan 2023Review(s) Completed, Editorial Evaluation Pending
05 Feb 2023Reviewer(s) Assigned
25 Mar 2023Editorial Decision: Revise Major
12 May 20231st Revision Received
13 May 2023Submission Checks Completed
13 May 2023Assigned to Editor
13 May 2023Review(s) Completed, Editorial Evaluation Pending
21 May 2023Reviewer(s) Assigned
31 May 2023Editorial Decision: Accept